Developing disease-modifying precision therapeutics that restore ABC transporter function for patients with serious genetic diseases.
Location: United States, Massachusetts, Cambridge
Total raised: $100M
Investors 4
| Date | Name | Website |
| 15.01.2022 | Omega Fund... | omegafunds... |
| - | DC Investm... | dcinvestme... |
| - | Forbion | forbion.co... |
| 30.10.2021 | Atlas Vent... | atlasventu... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.10.2021 | Series A | $100M | Omega Fund... |
Mentions in press and media 3
| Date | Title | Description |
| 15.10.2021 | Rectify Pharmaceuticals Raises $100M in Series A Financing | Rectify Pharmaceuticals, Inc., a Cambridge, Mass.-based biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics that restore ABC transporter function, closed a $100m Series A financing. The rou... |
| 14.10.2021 | Forbion Co-Leads New Investment in Rectify Pharmaceuticals Which Launches with $100m Series A Financing | Naarden, The Netherlands, 14 October 2021 – Forbion, a leading European life sciences venture capital firm, today announces the launch of a new portfolio company Rectify Pharmaceuticals, Inc. (‘Rectify’ or ‘the Company’). Forbion joins Atla... |
| 14.10.2021 | Rectify Pharmaceuticals Launches with $100 Million Series A Financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund | Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics that restore ABC transporter function, today announced it has closed a $100 million Series A... |